Home > Insider Trading > Filing (0000899243-17-028237)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
31791	Perkinelmer Inc	PKI	Laboratory Analytical Instruments (3826)	042052042

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1462948	Anders Frank Wilson	940 Winter Street Waltham MA 02451	Please See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-12-07	41,439	$26.15	106,581	No	4	M	Direct
Common Stock	Acquisiton	2017-12-07	29,052	$33.87	135,633	No	4	M	Direct
Common Stock	Disposition	2017-12-07	37,535	$70.14	65,142	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	NQ Stock Option (right to buy)	Disposition	2017-12-07	41,439	$0.00	41,439	$26.15
Common Stock	NQ Stock Option (right to buy)	Disposition	2017-12-07	29,052	$0.00	29,052	$33.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2019-02-07	No	4	M	Direct
0		2020-02-05	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by Mr. Wilson on November 7, 2017.
The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $70.00 to $70.40. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
The Reporting Person's direct holdings include shares acquired pursuant to the Reporting Person's (i) election to defer stock and/or compensation into the Deferred Compensation Plan, and/or (ii) reinvestment of dividends relating to the Reporting Person's account.
This option became exercisable in three equal annual installments beginning on February 7, 2013, which was the first anniversary of the date on which the option was granted.
This option became exercisable in three equal annual installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.